All In Biotech

Drug Trial Radar · NCT07868172

GST101 in Participants With RAS-Mutant Advanced Solid Tumors

A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GST101 in Participants With RAS-Mutant Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

172

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Oct 2028

Study completion Oct 2028

Sponsor

Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase I/II trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of oral GST101 in adult participants with RAS-mutant advanced solid tumors. Phase I consists of dose escalation and dose-expansion parts. Dose escalation uses accelerated titration design combined with 3+3 design to determine maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Safety, dose-limiting-toxicity (DLT), PK and preliminary efficacy will be assessed. Phase II (indication-exploration) enrolls participants in four tumor-specific cohorts including RAS-mutant NSCLC, colorectal cancer, pancreatic ductal adenocarcinoma and other advanced solid tumors refractory to standard-of-care therapies. Participants receive GST101 orally once-daily in 21-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or loss of clinical benefit. Tumor assessments follow RECIST 1.1. Safety, PK, QTc and exploratory biomarker analyses will be performed.

Conditions

  • RAS-mutant Advanced Solid Tumors

Interventions

  • GST101Drug

    5 mg oral tablet, administered once daily. Participants are assigned to different dose-level cohorts (10 mg, 20 mg, 40 mg, 60 mg, 80 mg, 100 mg). Fasting requirement: 1-hour fast prior to dosing and 2-hour fast after dosing. Each treatment cycle is 21-days. Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or no further clinical benefit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose-Limiting Toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Incidence and Severity of Treatment-Emergent Adverse Events (AEs) and Serious AEsTime frame: Up to 36 months
  3. Maximum Tolerated Dose (MTD)Time frame: Up to 12 months
  4. Recommended Phase 2 Dose (RP2D)Time frame: Up to 12 months
  5. Objective Response Rate (ORR)Time frame: Up to 36 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Not yet recruiting

  • Shandong Cancer Hospital and Institute

    Jinan, Shandong, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.